Trial Profile

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of MN-001 in Patients Diagnosed With Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 11 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tipelukast (Primary)
Indications Hypertriglyceridaemia; Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
Focus Therapeutic Use
Sponsors Medinova

08 Sep 2026 According to a MediciNova media release, topline data from Phase 2 MN-001-NATG-202 study in metabolic disease expected by end of Q3.
26 May 2026 According to a MediciNova media release, Top-line data are expected in the third quarter of 2026.
26 May 2026 Status changed from active, no longer recruiting to completed, according to a MediciNova media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com